Abstract
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin. Glycogen synthase kinase-3 (GSK-3) is regarded as a critical molecular link between the two histopathological hallmarks of the disease, namely senile plaques and neurofibrillary tangles. In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.
Alzheimer disease (AD) is a neurodegenerative disorder, first described by the German psychiatrist Alois Alzheimer in 1906. AD is the most common form of age-related dementia. The estimated annual incidence of this disease appears to increase exponentially with age, from approximately 53 new cases per 1,000 people between the ages of 65 and 74 to 231 new cases per 1,000 people over 85 (; ). Although mostly unknown, the etiology of AD is considered to be multifactorial. Only a negligible percentage of cases have a familial origin, while most are linked to environmental, non-genetic risk factors of diverse nature (). AD is characterized by a progressive loss of episodic memory and by cognitive and behavioral impairments. The most relevant histopathological hallmarks of the disease are extracellular senile plaques composed by amyloid-β (Aβ) protein and neurofibrillary tangles (NFTs), the latter formed mainly by hyperphosphorylated tau protein.
The anatomical changes in AD are highly selective for certain brain areas, although alterations can be widespread at advanced stages of the disease. Nevertheless, as one of the most affected brain structures, the entorhinal cortex (EC) is considered an invariant focus of pathology in all cases (Van Hoesen et al., 1991). Anatomical studies have revealed that the EC gives rise to axons that bi-directionally interconnect the hippocampus and the rest of the cortex. Accordingly, it is widely accepted that the EC functions as a gateway to the hippocampus, a brain structure that plays a key role in memory acquisition and consolidation. The EC–hippocampus disconnection that occurs in AD is believed to play a prominent role in the aggravation of the memory impairments that characterize this neurodegenerative disease.
Glycogen synthase kinase-3 (GSK-3) is a highly conserved protein-serine/threonine kinase that was first isolated from skeletal muscle in 1980 as one of five enzymes capable of phosphorylating glycogen synthase (). It was subsequently demonstrated that insulin triggers the inactivation of this kinase. In mammals, GSK-3 is encoded by two highly related genes encoding GSK-3α and GSK-3β, respectively. In the brain, GSK-3β regulates many crucial cellular processes, acting as a key switch that controls numerous signaling pathways (; ). The dysregulation of this kinase occurs in the development of cancer, diabetes, AD, schizophrenia, and bipolar disorder, among others. Thus, given its relevance in pathophysiological processes, GSK-3 β is widely considered a therapeutic target of interest.
GSK-3β AS A MOLECULAR LINK BETWEEN Aβ AND TAU
The Aβ peptide has been widely considered the cornerstone of AD pathogenesis, and its precursor protein APP is one of the most studied molecules in the field of AD research. The APP is a glycosylated surface membrane protein (). Aβ is a cleavage product derived from the transmembrane domain of this large precursor protein. APP undergoes post-translational processing, involving cleavage by various secretases and proteases, via two major pathways. Firstly, in the non-amyloidogenic pathway, APP is sequentially cleaved by α- and γ-secretases, thus giving rise to easily degradable fragments. Three members of the α-disintegrin and metalloproteinase (ADAM) family (ADAM-10, ADAM-17, and ADAM-9) have been proposed to form the α-secretase complex (; ). GSK-3β may down-regulate the activity of this complex by inhibiting ADAM activity (Zhang et al., 2012). In addition to another three proteins (APH1, PEN2, and nicastrin), presenilin (PS) 1 and 2 function as the catalytic core of the γ-secretase complex. GSK-3β also regulates Aβ production by interfering with APP cleavage at the γ-secretase complex step, since both APP and PS1 are also substrates of this kinase (). In vitro studies suggest that GSK-3β affects PS1 function, which is required for the generation of the toxic Aβ (Uemura et al., 2007).
In contrast, in the amyloidogenic pathway, APP is cleaved by β-secretase, generating a membrane-associated fragment (Zhang et al., 2012). Subsequently, γ-secretase releases Aβ, which tends to aggregate, giving rise to senile plaques and other insoluble oligomeric forms of the protein. The putative β-secretase, also known as β-site APP cleaving enzyme 1 (BACE1), is a type I transmembrane aspartyl protease whose active site is located on the luminal side of the membrane. The knock-down of bace1 prevents Aβ generation and abolishes amyloid pathology in mice expressing the Swedish mutation of APP (; ). The expression level and activity of BACE1 have been found to be elevated in AD patients (). Accordingly, GSK-3β inhibition reduces BACE1-mediated cleavage of APP through a NF-κB signaling-mediated mechanism. This observation thus suggests that the inhibition of GSK-3β reduces Aβ pathology ().
In vitro studies (Takashima et al., 1996b) and transgenic animal models of AD (Terwel et al., 2008) indicate that Aβ activates GSK-3β signaling (Takashima et al., 1996a, b) by preventing inhibitory phosphorylation of this enzyme in the case of in vitro studies and by an independent mechanism in the case of animal studies. A similar increase in GSK-3β activity has been observed in the brains of AD patients (). A feed-forward loop is established after GSK-3β pathological activation by Aβ, which subsequently contributes to abnormal APP processing and to synaptic failure (). Consistent with this, GSK-3β inhibition has been shown to reduce Aβ production in AD murine models (Phiel et al., 2003; Rockenstein et al., 2007b) and to decrease Aβ-induced neurotoxicity in cultured neurons ().
In post-mitotic neurons, the microtubule network is of particular significance in supporting axon function. Microtubule-associated proteins (MAPs) facilitate and regulate microtubule formation and stability. Tau is a MAP that is found mainly in the axonal compartment under physiological conditions. Tau associates with microtubules and stabilizes their polymerization. It has been suggested that the presence of tau is required for Aβ-induced toxicity (Rapoport et al., 2002; Santacruz et al., 2005; Roberson et al., 2007). NFTs comprise mainly hyperphosphorylated forms of tau protein. In contrast to normal tau, the hyperphosphorylated form of the protein acquires the shape of paired helical filaments (PHF-tau). Accumulating evidence indicates that the phosphorylated state of tau is closely associated with AD pathology (). Accordingly, Aβ induces the formation of tau fibrils in culture (). PHF-tau has been described to be an aggregated and insoluble deposit in the somatodendritic compartment (). In addition, this form of tau is often truncated at the C-terminal domain and is highly resistant to the action of phosphatases and proteases. While non-phosphorylated tau is a flexible protein, PHF-tau is an insoluble misfolded protein. During the course of NFT formation, tau progressively acquires a rigid conformation.
The distinct phosphorylation states of tau correspond to its physiological roles (; Sergeant et al., 2008), and phosphorylation of some of its serine/threonine residues elicits a biological effect (). The three tau kinases, GSK-3β, CDK-5, and PKA, associate with both tau and microtubules. Although they show a wide spectrum of phosphorylation, the major phosphorylatable sites of tau for each kinase are limited in preference (). Multisite phosphorylation occurs in PHF-tau and is explained by the catalytic activities of the different kinases, although the functional significance of this phenomenon is not completely understood. Indeed, a direct association of tau with GSK-3β takes place as a functional unit (Sun et al., 2002; ). Although GSK-3β phosphorylates at least 36 residues in tau (), the main phosphorylation sites identified for this kinase are Ser199, Thr231, Ser396, and Ser413 (). A moderate phosphorylation of Ser46, Thr50, and Ser202/Thr205 has also been reported (), and minor phosphorylation of other residues has been described (). A complete description of these phosphorylation sites is provided in an extensive review by .
In the pre-tangle stage of AD, scattered deposits of phospho-Thr231-tau are detected in the brains of patients (). Interestingly, similar to many other residues of tau, the phosphorylation of Thr231 demands the combined action of CDK-5 and GSK-3β (; ). GSK-3β requires a priming phosphorylation of this residue by other tau kinases. This phosphorylation reduces tau binding to microtubules (Sengupta et al., 1998). A similar mechanism has been described for Ser404 and other residues. Thus, the combined action of CDK-5 and GSK-3β seems to be required for the development of the epitope characteristics of PHF-tau (Plattner et al., 2006; Sengupta et al., 2006). Interestingly, the protein phosphatases PP-1 and PP-2 effectively dephosphorylate these sites, in such a way that the overall tau phosphorylation state is determined by the balance between kinase and phosphatase action. Subsequently, cleavage and conformational changes of tau occur after its phosphorylation. After neuronal cell death, intracellular NFTs are released into the extracellular space (). Interestingly, growing evidence indicates that hyperphosphorylated tau activates GSK-3β through an increase in oxidative stress, neuroinflammation, and apoptosis (Saeki et al., 2011). In addition, GSK-3β impairs lysosomal acidification, a process that entails an inadequate clearance of non-functional proteins ().
In summary, increased GSK-3β activity has been used to model events occurring in AD, interventions that exacerbate cognitive impairments, and neuropathology in rodent models of AD (). Conditional overexpression of GSK-3β in mouse hippocampal neurons results in impaired performance in the Morris water maze, hyperphosphorylation of tau, reactive astrogliosis and microgliosis, and neuronal death (; ). Restoring normal levels of GSK-3β activity reverses spatial memory deficits, reduces tau hyperphosphorylation, and decreases reactive gliosis and neuronal death (). The deletion of tau in GSK-3β-overexpressing mice significantly ameliorates memory impairments, thus indicating that tau phosphorylation contributes to this cognitive impairment ().
PHYSIOLOGICAL AND PATHOLOGICAL REGULATION OF GSK-3β ACTIVITY
GSK-3β is constitutively active in most tissues and most commonly regulated by inhibitory phosphorylation on Ser9. GSK-3β can be phosphorylated on this serine by several kinases. This observation allows for an effective mechanism for several intracellular signaling pathways to control the activity of this kinase. However, the dysregulation of these signal transduction pathways results in failure to adequately repress GSK-3β, thus allowing GSK-3β to remain abnormally active. Such a status contributes to various pathologies, including neurodegenerative and mood disorders, diabetes, and cancer.
The most relevant extracellular signaling pathway known to regulate GSK-3β activity is that of insulin/insulin-like growth factor I (Figure 1). In addition, a number of kinases phosphorylate Ser9 of GSK-3β in the context of specific signaling pathways: PKB targets GSK-3β in response to insulin (Sutherland et al., 1993); PKA phosphorylates GSK-3β in Ser9 in response to cAMP (); p90RSK/MAPKAP kinase-1 phosphorylates GSK-3β following activation by EGF or PDGF (Sutherland and Cohen, 1994; ); and p70S6K targets GSK-3β in response to stimulation by insulin and other growth factors ().
FIGURE 1
Interestingly, Aβ interferes not only with insulin but also with Wnt signaling pathways (Townsend et al., 2007; ). GSK-3β is a key transducer of the Wnt pathway (Figure 1), the components of which are involved in AD onset (). It has been suggested that auto-inhibitory phosphorylation on Ser9 participates in the regulation of GSK-3β activity in response to Wnt (Saito et al., 1994; ). In the canonical Wnt signaling pathway, Wnt stabilizes levels of β-catenin. Subsequently, stabilized β-catenin initiates the transcription of target genes. GSK-3β phosphorylates several components of this transduction pathway, β-catenin being the most widely characterized. Phosphorylated β-catenin is recognized by ubiquitin and targeted for proteasomal degradation (Wu and He, 2006). Consequently, signals that modify GSK-3β activity are expected to alter β-catenin levels (). In addition, other components of Wnt signaling pathway, such as DKK1, negatively regulate these pathways, thus activating GSK-3β and contributing to the pathological events triggered by Aβ ().
It has been proposed that GSK-3β activity also depends on the phosphorylation of Tyr216 (). The underlying mechanisms responsible for regulating tyrosine phosphorylation of GSK-3β remain controversial. In addition, it is still unclear whether GSK-3β autophosphorylation is an intramolecular or intermolecular event.
An interesting alternative regulatory mechanism of GSK-3β activity involves the action of the calcium-dependent protease calpain. GSK-3β is a calpain substrate () and its cleavage by calpain produces the release of the inhibitory domain containing Ser9. Only in the GSK-3α isoform (but not in GSK-3β) is this region surrounded by glycine stretches, a feature that has been proposed to differentially regulate inhibitory phosphorylation and cleavage by calpain in both isoforms ().
NEURAL CONSEQUENCES OF THE DYSREGULATION OF GSK-3β ACTIVITY
CHOLINERGIC SYSTEM ALTERATION
A marked loss of cholinergic neurons in certain cortical areas is a well-known feature of AD brain (Whitehouse et al., 1981; Plotkin and Jarvik, 1986). It has been proposed that GSK-3β plays a key role in choline metabolism, which involves the regulation of choline acetyltransferase (ChAT) and acetylcholinesterase (Yates et al., 1983; Samadi et al., 2011). In fact, the loss of cholinergic neurons in the basal forebrain and hippocampus correlates with a transient decrease in Ser9 phosphorylation of GSK-3β and a concomitant increase in tau phosphorylation (; Wang et al., 2009). In addition, cholinergic stimulation in the hippocampus, striatum, and cortex causes a rapid increase in Ser9 phosphorylation of GSK-3β (Wang et al., 2009).
AXONAL TRANSPORT AND MICROTUBULE DYNAMICS IMPAIRMENT
Axonopathy and cytoskeletal disruption play a crucial role in AD (; Robert and Mathuranath, 2007). GSK-3β has the capacity to phosphorylate several MAPs, thus regulating axonal stability through direct interaction with microtubules. GSK-3β-phosphorylated forms of tau and MAP-2 exhibit decreased affinity toward microtubules and are less stable (; Sanchez et al., 2000; Zumbrunn et al., 2001). This microtubule destabilization is detrimental for the maintenance of axonal structure and appropriate synapse function (Sergeant et al., 2008). Importantly, Aβ plaques can lead to axonal dystrophy, causing profound impairment of axonal transport, great detriment to cognitive function, extensive synapse loss, and cell death (Rauk, 2008). Growing evidence indicates that axonal transport failure makes a significant contribution to AD pathology (Pope et al., 1993).
During neural development, GSK-3β is involved in axon formation and elongation (). In this regard, it impairs mitochondrial anterograde and retrograde axonal transport in vitro, a process that involves tau and MAP-1B, respectively (; ; ), and these alterations can have severe consequences on synapse function as a result of energy depletion. Accordingly, tau overexpression disrupts axonal transport, causing vesicular aggregation, a phenomenon reversed by GSK-3β inhibitors (Soutar et al., 2010).
In addition, PS1 regulates kinesin-related axonal transport by a mechanism involving GSK-3β activity (Ryan and Pimplikar, 2005) and the modulation of its role in controlling kinesin binding to microtubules at sites of vesicle release (Pigino et al., 2003).
APOPTOSIS
Interestingly, GSK-3β promotes both pro-and anti-apoptotic effects. In this regard, it regulates the two major apoptotic pathways: intrinsic and extrinsic. GSK-3β triggers cell death through the activation of the mitochondrial intrinsic pro-apoptotic pathway while it inhibits the death receptor-mediated extrinsic apoptotic pathway (). After activation of the former, this kinase induces apoptosis in response to a wide range of detrimental stimuli, such as DNA damage (Watcharasit et al., 2003), hypoxia (), growth factor deprivation (Pap and Cooper, 1998; ), and heat shock (). As a part of this pro-apoptotic cascade, GSK-3β phosphorylates and inhibits eIF2B (Welsh and Proud, 1993; Pap and Cooper, 2002). A murine model of neuronal GSK-3β overexpression developed by our group shows enhanced apoptosis in certain sensitive areas of the brain such as the hippocampal formation, which is crucial for memory and learning and strongly affected in AD (; ). Although the exact mechanism by which GSK-3β overexpression induces apoptosis in these cells is unclear, it has been proposed that the combination of cell-autonomous effects and other effects indirectly mediated by inflammatory changes act in a coordinated manner to induce hippocampal neuron death (). However, given the regulation of the extrinsic apoptotic pathway by GSK-3β, it should be considered that this kinase modulates crucial steps in each of the two major pathways of apoptosis, but in opposing directions. Consequently, inhibitors of GSK-3β provide protection from intrinsic apoptotic signaling but potentiate that of extrinsic apoptosis (). These observations should be taken into account when designing new therapeutic approaches and novel GSK-3β inhibitors.
SYNAPTIC EFFECTS
Synaptic loss is currently the best neurobiological correlate of cognitive deficits in AD. In addition to the synapse loss caused by neuronal cell death, living neurons lose synapses in AD (). It has been proposed that the mechanism allowing information storage in the brain involves changes in synaptic connection weights, including long-term potentiation (LTP) and long-term depression (LTD). The finding that LTP inhibits GSK-3β activity and that this kinase is required for LTD suggests that LTP regulates LTD (Peineau et al., 2007). Although the exact mechanism underlying this regulation remains unclear, it has been demonstrated that constitutive GSK-3β activity enhances basal α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) endocytosis (Wei et al., 2010). This phenomenon, leads to the dissociation of AMPAR-containing vesicles from kinesin (). In addition, tau and PS1 may be additional targets for GSK-3β regulation of synaptic plasticity, or, alternatively, different transcription factors or miRNAs may be involved in the protein synthesis-dependent phase of LTD ().
Of particular interest is whether the balance between LTP and LTD leads to functional impairments in memory storage similar to those described in AD (). LTD induces the removal of AMPARs from individual synapses () in a process known as synapse silencing. These silent synapses are either reactivated through new AMPAR insertion (unsilencing; ; ) or eliminated (; ). Synapse elimination is particularly important during development and crucial for pruning unnecessary synaptic connections (Rabacchi et al., 1992; ). In fact, NMDAR-triggered apoptosis requires AMPAR endocytosis (Wang et al., 2004), a process known as synaptosis. In adulthood, synaptosis is down-regulated, and it is assumed that NMDAR-related LTD is used for adjusting synaptic weights rather than for eliminating synapses. Collingridge and colleagues suggested that neurodegeneration is often triggered by the reactivation of synaptosis, which leads to apoptosis of vulnerable neuronal populations (). The imbalance between these mechanisms may lead to the pathological elimination of synapses, which in turn leads to neuronal death. In this regard, we have demonstrated that neuronal GSK-3β overexpression causes a drastic decrease in postsynaptic density number and volume in hippocampal granule neurons (), a phenomenon that may be related to cognitive impairment and altered LTP generation previously observed in these mice (; ). In agreement, Aβ causes synaptic toxicity (; Witton et al., 2010). The use of GSK-3β inhibitors protects synapses from the deleterious effects of Aβ (Shipton et al., 2011), thus suggesting that GSK-3β activation is required for the pathological effect of Aβ on synaptic plasticity.
INFLAMMATION
Among the functions regulated by GSK-3β, inflammation has recently emerged as one of the most relevant for neurodegenerative disorders (Sudduth et al., 2013). GSK-3β itself is an important positive regulator of the inflammatory process (; ). Within the brain, microglial cells are considered to be equivalent to macrophages in the periphery and key guardian immune cells. Numerous stressors activate microglia, including neurodegenerative diseases, leading to a chronic inflammatory response and migration of responsive cells from the periphery. During long-term inflammatory responses, chronically activated (primed) glia appear to be detrimental to neuronal function and survival. Therefore, it is relevant that GSK-3β has been identified as a prominent regulator of inflammation. GSK-3β promotes the production of various pro-inflammatory cytokines, such as interleukin-6 (IL-6), IL-1β, and tumor necrosis factor (TNF; ). In addition, this kinase decreases the production of the anti-inflammatory cytokine IL-10. Remarkably, in vivo administration of GSK-3β inhibitors confers protection from endotoxin shock (). Data from our group showed that GSK-3β overexpression in neurons leads to the appearance of a unique pattern of cytokines in the brain in vivo (). In addition, we have demonstrated that this pro-inflammatory environment is detrimental for immature neurons as it inhibits their appropriate maturation () and leads them to acquire an aberrant morphology (named “V” shape) markedly similar to that found in AD patient granule neurons ().
CELL CYCLE DYSREGULATION
The formation of dynamically re-arranged synaptic connections during continuous structural remodeling entails that neurons must permanently withdraw from the cell cycle (). As elegantly exposed in the “Dr. Jekyll and Mr. Hyde concept,” formulated by Arendt, after leaving the cell cycle, differentiated neurons modulate synaptic plasticity through molecular mechanisms primarily developed to control proliferation (, ). The up-regulation of a various molecular effectors involved in the activation and progression of the cell cycle occurs at early stages of neurodegeneration in AD (; Nagy et al., 1997a, b). Although the cause of this failure remains to be elucidated, recent evidence indicates that molecular mechanisms controlling synaptic plasticity and cell cycle are shared in the same cells, and, consequently, attempts to increase plasticity during initial stages of AD are sometimes disastrous for hippocampal function. At the molecular level, the Sonic hedgehog (Shh) and Wnt signaling pathways cooperate to orchestrate cellular proliferation, differentiation, and pattern formation during both development and adult neurogenesis. As previously discussed, GSK-3β plays a crucial role in modulating both pathways. Although the underlying mechanism regulating GSK-3β activity in response to Shh remains to be determined, Zhang et al. (2005) proposed the formation of a multi-protein complex similar to that required for efficient phosphorylation of β-catenin in the Wnt pathway. However, the physiological relevance of this interaction has yet to be revealed.
ADULT HIPPOCAMPAL NEUROGENESIS
New neurons are continuously added to the hippocampal dentate gyrus (DG) throughout lifetime (; ). During differentiation stages, newborn neurons sequentially increase their dendritic tree complexity and send axons toward the CA3 region (Zhao et al., 2006). Growing evidence indicates that newborn neurons are crucial for hippocampal function and hippocampal-dependent memory (). One of the most important regulators of adult hippocampal neurogenesis (AHN) is GSK-3β. In this regard, it has been demonstrated that overexpression of this kinase impairs adult neurogenesis (Sirerol-Piquer et al., 2011; ) and causes a depletion in the number of proliferative clusters within the hippocampal DG. In addition, we have recently reported that GSK-3β overexpression has dual effects on newborn neurons, blocking the differentiation of newborn neurons, thus supporting the notion that their maturation is impaired. We have observed that GSK-3β overexpression leads to alterations in the rate of death and survival of newborn neurons, as well as in the expression pattern of the immature neuron marker doublecortin (). In accordance, Spittaels et al. (2002) demonstrated that GSK-3β influences the post-natal maturation of neurons in vivo in a transgenic model overexpressing a constitutively active form of the enzyme. In addition, overexpression of this kinase causes morphological and connectivity alterations similar to those observed in the granule neurons of AD patients (). Given the relevance of newborn neurons in hippocampal-dependent learning, it is reasonable to assume that the alterations in AHN lead to cognitive impairments. In fact, murine model overexpressing GSK-3β in the hippocampus shows impaired hippocampal-dependent learning ().
AD THERAPIES INVOLVING GSK-3β INHIBITION
Growing evidence indicates that GSK-3β contributes to the pathology of several neurodegenerative diseases. Thus, there is increasing interest in applying GSK-3β inhibitors to treat these disorders. Lithium is a GSK-3 inhibitor that binds directly to GSK-3β () and increases the inhibitory phosphorylation in Ser9 of GSK-3β (). Lithium is used as a mood stabilizer in patients suffering from mood disorders. Various effects of lithium are caused by GSK-3β inhibition (), and lithium administration reduces the neuropathology and cognitive deficits in rats that have received intra-hippocampal injections of Aβ (), rats overexpressing GSK-3β (), and several murine models overexpressing human APP (Rockenstein et al., 2007b; ; Toledo and Inestrosa, 2010). However, some studies report poor effects of lithium on behavior in other murine models of AD (; ; Sudduth et al., 2012). It is interesting to note that although certain cognitive tasks are improved by lithium treatment in healthy rodents, this metal does not significantly affect cognitive performance.
Recent years have witnessed the development of an increasing number of novel GSK-3β inhibitors, many of which are ATP-competitive. However, particularly promising are the non-ATP-competitive GSK-3β inhibitors, since they tend to be more selective and less toxic (). The classical ATP-competitive GSK-3 inhibitors include Indirubin (), Paullone compounds (), SB415286 and SB216763 (), and AR-A014418 (). Several well-known non-competitive ATP binding site inhibitors of GSK-3 are L803-mts (Plotkin et al., 2003; ), TDZD-8 (), and VP0.7 (Palomo et al., 2011). The treatment of healthy rodents with GSK-3β inhibitors produces no remarkable effects on behavioral cognitive scores (Thotala et al., 2008). Conversely, genetic reduction of GSK-3β activity appears to be detrimental for hippocampal memory acquisition (). In contrast, GSK-3β overexpression (both the native and constitutively active forms of the enzyme) leads to cognitive impairment (; ). In this regard, inhibitors of GSK-3β have been reported to rescue cognitive deficits in several murine models of AD. Treatment with NP12, AR-A014418, and Indirubin decreases memory deficits in the Morris water maze and reduces tau phosphorylation and amyloid deposition in various models of transgenic mice overexpressing human APP (Sereno et al., 2009; ; ). In addition, 5XFAD mice treated with L803-mts exhibit improved hippocampal-dependent learning capacity (). Genetic approaches aimed to knock down either GSK-3α or GSK-3β have also been shown to improve cognitive impairments in several murine models of AD (Rockenstein et al., 2007a, b; ).
The promising ability of GSK-3 inhibitors to alleviate the AD-like phenotype of various murine models of AD has brought about several clinical studies in patients with this neurodegenerative disease, although contradictory data regarding the success of these treatments have been reported by different clinical trials (). It should be taken into account that GSK-3 is essential for cell life, and there is a concern that its inhibition could prevent cells from operating normally ().
Lithium has been shown to exert certain protection against the development of cognitive impairments in bipolar disorder patients (Nunes et al., 2007; ). Importantly, patients in early-stage AD receiving lithium treatment showed improved cognitive function (; , ), although other studies showing no such enhancement have also been reported (; Pomara, 2009).
CONCLUSIONS AND FURTHER DIRECTIONS
GSK-3β is not a conventional kinase. It plays critical roles in neurodevelopment and in both physiological and pathological aging. In AD, a functional link between Aβ and tau unequivocally implicates the dysregulation of GSK-3β activity. In recent decades, Aβ was considered the cornerstone of AD etiology. However, the present consensus is that the disease has a multifactorial origin. Growing evidence supports inflammation as one of the most deleterious inputs to the aging brain. Given the relevance of GSK-3β in regulating crucial steps of the inflammatory cascade, efforts should be channeled into the development of novel and selective inhibitors that safely regulate the activity of this kinase, and, in parallel, block the inflammatory and self-propagating cascade that it triggers in previously damaged brain areas. Although the involvement of GSK-3β in multiple pathways controlling most of the crucial aspects of cell physiology complicates the design of specific inhibitors, it is of paramount importance to address the whole spectrum of GSK-3β actions on cell biology under both physiological and pathological conditions. A promising avenue are also regenerative strategies focused on the capacity of certain neural populations to be continuously generated and integrated into pre-existing neural circuits (adult neurogenesis). Given the pivotal role played by GSK-3β in the regulation of these processes, it is imperative to perform exhaustive research into the therapeutic potential of GSK-3β inhibitors. Such drugs would allow the normal development and functional integration of newborn neurons in the hippocampal formation previously damaged by the progression of the disease.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
REFERENCES
1
AlvarezA. R.GodoyJ. A.MullendorffK.OlivaresG. H.BronfmanM.InestrosaN. C. (2004). Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons.Exp. Cell Res.297186–196. 10.1016/j.yexcr.2004.02.028
2
Alzheimer’s Association. (2012). 2012 Alzheimer’s disease facts and figures.Alzheimers Dement.8131–168. 10.1016/j.jalz.2012.02.001
3
ArendtT. (2003). Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity.Prog. Neurobiol.7183–248. 10.1016/j.pneurobio.2003.09.007
4
ArendtT. (2009). Synaptic degeneration in Alzheimer’s disease.Acta Neuropathol.118167–179. 10.1007/s00401-009-0536-x
5
ArendtT.RodelL.GartnerU.HolzerM. (1996). Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer’s disease.Neuroreport73047–3049. 10.1097/00001756-199611250-00050
6
AugustinackJ. C.SchneiderA.MandelkowE. M.HymanB. T. (2002). Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease.Acta Neuropathol.10326–35. 10.1007/s004010100423
7
AvrahamiL.FarfaraD.Shaham-KolM.VassarR.FrenkelD.Eldar-FinkelmanH. (2013). Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.J. Biol. Chem.2881295–1306. 10.1074/jbc.M112.409250
8
BartzokisG.CummingsJ. L.SultzerD.HendersonV. W.NuechterleinK. H.MintzJ. (2003). White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study.Arch. Neurol.60393–398. 10.1001/archneur.60.3.393
9
BastrikovaN.GardnerG. A.ReeceJ. M.JerominA.DudekS. M. (2008). Synapse elimination accompanies functional plasticity in hippocampal neurons.Proc. Natl. Acad. Sci. U.S.A.1053123–3127. 10.1073/pnas.0800027105
10
BeurelE.JopeR. S. (2006). The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.Prog. Neurobiol.79173–189. 10.1016/j.pneurobio.2006.07.006
11
BhatR.XueY.BergS.HellbergS.OrmoM.NilssonY.et al (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.J. Biol. Chem.27845937–45945. 10.1074/jbc.M306268200
12
BhattD. H.ZhangS.GanW. B. (2009). Dendritic spine dynamics.Annu. Rev. Physiol.71261–282. 10.1146/annurev.physiol.010908.163140
13
BijurG. N.De SarnoP.JopeR. S. (2000). Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium.J. Biol. Chem.2757583–7590. 10.1074/jbc.275.11.7583
14
BillingsleyM. L.KincaidR. L. (1997). Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.Biochem. J.323(Pt 3)577–591.
15
BischofbergerJ. (2007). Young and excitable: new neurons in memory networks.Nat. Neurosci.10273–275. 10.1038/nn0307-273
16
BlennowK.de LeonM. J.ZetterbergH. (2006). Alzheimer’s disease.Lancet368387–403. 10.1016/S0140-6736(06)69113-7
17
BradleyC. A.PeineauS.TaghibiglouC.NicolasC. S.WhitcombD. J.BortolottoZ. A.et al (2012). A pivotal role of GSK-3 in synaptic plasticity.Front. Mol. Neurosci.5:13. 10.3389/fnmol.2012.00013
18
BrettevilleA.PlanelE. (2008). Tau aggregates: toxic, inert, or protective species?J. Alzheimers Dis.14431–436.
19
BuxbaumJ. D.ThinakaranG.KoliatsosV.O’CallahanJ.SluntH. H.PriceD. L.et al (1998). Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path.J. Neurosci.189629–9637.
20
CaccamoA.OddoS.TranL. X.LaFerlaF. M. (2007). Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.Am. J. Pathol.1701669–1675. 10.2353/ajpath.2007.061178
21
CaiH.WangY.McCarthyD.WenH.BorcheltD. R.PriceD. L.et al (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons.Nat. Neurosci.4233–234. 10.1038/85064
22
CaiZ.ZhaoY.ZhaoB. (2012). Roles of glycogen synthase kinase 3 in Alzheimer’s disease.Curr. Alzheimer Res.9864–879. 10.2174/156720512802455386
23
CoghlanM. P.CulbertA. A.CrossD. A.CorcoranS. L.YatesJ. W.PearceN. J.et al (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.Chem. Biol.7793–803. 10.1016/S1074-5521(00)00025-9
24
ColemanP. D.YaoP. J. (2003). Synaptic slaughter in Alzheimer’s disease.Neurobiol. Aging241023–1027. 10.1016/j.neurobiolaging.2003.09.001
25
CrossD. A.AlessiD. R.CohenP.AndjelkovichM.HemmingsB. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.Nature378785–789. 10.1038/378785a0
26
ChristianS. L.SimsP. V.GoldM. R. (2002). The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3.J. Immunol.169758–769. 10.4049/jimmunol.169.2.758
27
ChunJ.KwonT.LeeE. J.KimC. H.HanY. S.HongS. K.et al (2004). 14-3-3 Protein mediates phosphorylation of microtubule-associated protein tau by serum- and glucocorticoid-induced protein kinase 1.Mol. Cells18360–368.
28
CullenW. K.SuhY. H.AnwylR.RowanM. J. (1997). Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments.Neuroreport83213–3217. 10.1097/00001756-199710200-00006
29
De FerrariG. V.ChaconM. A.BarriaM. I.GarridoJ. L.GodoyJ. A.OlivaresG.et al (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils.Mol. Psychiatry8195–208. 10.1038/sj.mp.4001208
30
del SerT.SteinwachsK. C.GertzH. J.AndresM. V.Gomez-CarrilloB.MedinaM.et al (2013). Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study.J. Alzheimers Dis.33205–215. 10.3233/JAD-2012-120805
31
DengY.XiongZ.ChenP.WeiJ.ChenS. S.YanZ. (2014). beta-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3.Neurobiol. Aging35449–459. 10.1016/j.neurobiolaging.2013.08.031
32
DewachterI.RisL.JaworskiT.SeymourC. M.KremerA.BorghgraefP.et al (2009). GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at serine-9.Neurobiol. Dis.35193–200. 10.1016/j.nbd.2009.04.003
33
DicksonD. W.Ksiezak-RedingH.LiuW. K.DaviesP.CroweA.YenS. H. (1992). Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.Acta Neuropathol.84596–605. 10.1007/BF00227736
34
DingY.QiaoA.FanG. H. (2010). Indirubin-3′-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease.Neurobiol. Dis.39156–168. 10.1016/j.nbd.2010.03.022
35
DobleB. W.WoodgettJ. R. (2007). Role of glycogen synthase kinase-3 in cell fate and epithelial–mesenchymal transitions.Cells Tissues Organs18573–84. 10.1159/000101306
36
DuJ.WeiY.LiuL.WangY.KhairovaR.BlumenthalR.et al (2010). A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors.Proc. Natl. Acad. Sci. U.S.A.10711573–11578. 10.1073/pnas.0913138107
37
EgashiraY.TanakaT.SoniP.SakuragiS.Tominaga-YoshinoK.OguraA. (2010). Involvement of the p75(NTR) signaling pathway in persistent synaptic suppression coupled with synapse elimination following repeated long-term depression induction.J. Neurosci. Res.883433–3446. 10.1002/jnr.22505
38
EmbiN.RylattD. B.CohenP. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase.Eur. J. Biochem.107519–527. 10.1111/j.1432-1033.1980.tb06059.x
39
EngelT.HernandezF.AvilaJ.LucasJ. J. (2006). Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.J. Neurosci.265083–5090. 10.1523/JNEUROSCI.0604-06.2006
40
FangX.YuS. X.LuY.BastR. C.WoodgettJ. R.Jr.MillsG. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.Proc. Natl. Acad. Sci. U.S.A.9711960–11965. 10.1073/pnas.220413597
41
FerrariA.HoerndliF.BaechiT.NitschR. M.GotzJ. (2003). beta-Amyloid induces paired helical filament-like tau filaments in tissue culture.J. Biol. Chem.27840162–40168. 10.1074/jbc.M308243200
42
FiorentiniA.RosiM. C.GrossiC.LuccariniI.CasamentiF. (2010). Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice.PLoS ONE5:e14382. 10.1371/journal.pone.0014382
43
FordeJ. E.DaleT. C. (2007). Glycogen synthase kinase 3: a key regulator of cellular fate.Cell. Mol. Life Sci.641930–1944. 10.1007/s00018-007-7045-7
44
ForlenzaO. V.de PaulaV. J.Machado-VieiraR.DinizB. S.GattazW. F. (2012). Does lithium prevent Alzheimer’s disease?Drugs Aging29335–342. 10.2165/11599180-000000000-00000
45
ForlenzaO. V.DinizB. S.RadanovicM.SantosF. S.TalibL. L.GattazW. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.Br. J. Psychiatry198351–356. 10.1192/bjp.bp.110.080044
46
FukumotoS.HsiehC. M.MaemuraK.LayneM. D.YetS. F.LeeK. H.et al (2001). Akt participation in the Wnt signaling pathway through Dishevelled.J. Biol. Chem.27617479–17483. 10.1074/jbc.C000880200
47
Fuster-MatanzoA.Llorens-MartinM.de BarredaE. G.AvilaJ.HernandezF. (2011). Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3beta.PLoS ONE6:e27262. 10.1371/journal.pone.0027262
48
Fuster-MatanzoA.Llorens-MartinM.Jurado-ArjonaJ.AvilaJ.HernandezF. (2012). Tau protein and adult hippocampal neurogenesis.Front. Neurosci.6:104. 10.3389/fnins.2012.00104
49
Fuster-MatanzoA.Llorens-MartinM.Sirerol-PiquerM. S.Garcia-VerdugoJ. M.AvilaJ.HernandezF. (2013). Dual effects of increased glycogen synthase kinase-3beta activity on adult neurogenesis.Hum. Mol. Genet.221300–1315. 10.1093/hmg/dds533
50
GhosalK.VogtD. L.LiangM.ShenY.LambB. T.PimplikarS. W. (2009). Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain.Proc. Natl. Acad. Sci. U.S.A.10618367–18372. 10.1073/pnas.0907652106
51
GodemannR.BiernatJ.MandelkowE.MandelkowE. M. (1999). Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain.FEBS Lett.454157–164. 10.1016/S0014-5793(99)00741-3
52
Gomez de BarredaE.PerezM.Gomez RamosP.de CristobalJ.Martin-MaestroP.MoranA.et al (2010). Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits.Neurobiol. Dis.37622–629. 10.1016/j.nbd.2009.11.017
53
Gomez-SintesR.HernandezF.BortolozziA.ArtigasF.AvilaJ. J.ZaratinP.et al (2007). Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.EMBO J.262743–2754. 10.1038/sj.emboj.7601725
54
Gomez-SintesR.HernandezF.LucasJ. J.AvilaJ. (2011). GSK-3 mouse models to study neuronal apoptosis and neurodegeneration.Front. Mol. Neurosci.4:45. 10.3389/fnmol.2011.00045
55
Goni-OliverP.AvilaJ.HernandezF. (2009). Calpain-mediated truncation of GSK-3 in post-mortem brain samples.J. Neurosci. Res.871156–1161. 10.1002/jnr.21932
56
Goni-OliverP.LucasJ. J.AvilaJ.HernandezF. (2007). N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.J. Biol. Chem.28222406–22413. 10.1074/jbc.M702793200
57
GotzJ.ProbstA.SpillantiniM. G.SchaferT.JakesR.BurkiK.et al (1995). Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform.EMBO J.141304–1313.
58
HangerD. P.ByersH. L.WrayS.LeungK. Y.SaxtonM. J.SeereeramA.et al (2007). Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis.J. Biol. Chem.28223645–23654. 10.1074/jbc.M703269200
59
HashiguchiM.HashiguchiT. (2013). Kinase-kinase interaction and modulation of tau phosphorylation.Int. Rev. Cell Mol. Biol.300121–160. 10.1016/B978-0-12-405210-9.00004-7
60
HebertL. E.BeckettL. A.ScherrP. A.EvansD. A. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050.Alzheimer Dis. Assoc. Disord.15169–173. 10.1097/00002093-200110000-00002
61
HernandezF.BorrellJ.GuazaC.AvilaJ.LucasJ. J. (2002). Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.J. Neurochem.831529–1533. 10.1046/j.1471-4159.2002.01269.x
62
HolsingerR. M.McLeanC. A.BeyreutherK.MastersC. L.EvinG. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease.Ann. Neurol.51783–786. 10.1002/ana.10208
63
HooperC.MarkevichV.PlattnerF.KillickR.SchofieldE.EngelT.et al (2007). Glycogen synthase kinase-3 inhibition is integral to long-term potentiation.Eur. J. Neurosci.2581–86. 10.1111/j.1460-9568.2006.05245.x
64
HoshiM.TakashimaA.NoguchiK.MurayamaM.SatoM.KondoS.et al (1996). Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain.Proc. Natl. Acad. Sci. U.S.A.932719–2723. 10.1073/pnas.93.7.2719
65
HurtadoD. E.Molina-PorcelL.CarrollJ. C.MacdonaldC.AboagyeA. K.TrojanowskiJ. Q.et al (2012). Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer’s disease.J. Neurosci.327392–7402. 10.1523/JNEUROSCI.0889-12.2012
66
IllenbergerS.Zheng-FischhoferQ.PreussU.StamerK.BaumannK.TrinczekB.et al (1998). The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease.Mol. Biol. Cell91495–1512. 10.1091/mbc.9.6.1495
67
IsaacJ. T.NicollR. A.MalenkaR. C. (1995). Evidence for silent synapses: implications for the expression of LTP.Neuron15427–434. 10.1016/0896-6273(95)90046-2
68
Jimenez-MateosE. M.Gonzalez-BillaultC.DawsonH. N.VitekM. P.AvilaJ. (2006). Role of MAP1B in axonal retrograde transport of mitochondria.Biochem. J.39753–59. 10.1042/BJ20060205
69
Johnson-FarleyN. N.TravkinaT.CowenD. S. (2006). Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons.J. Pharmacol. Exp. Ther.3161062–1069. 10.1124/jpet.105.094433
70
JopeR. S. (2003). Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes.Trends Pharmacol. Sci.24441–443. 10.1016/S0165-6147(03)00206-2
71
JopeR. S. (2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.Front. Mol. Neurosci.4:16. 10.3389/fnmol.2011.00016
72
JopeR. S.YuskaitisC. J.BeurelE. (2007). Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.Neurochem. Res.32577–595. 10.1007/s11064-006-9128-5
73
Kaidanovich-BeilinO.MilmanA.WeizmanA.PickC. G.Eldar-FinkelmanH. (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus.Biol. Psychiatry55781–784. 10.1016/j.biopsych.2004.01.008
74
KangJ.LemaireH. G.UnterbeckA.SalbaumJ. M.MastersC. L.GrzeschikK. H.et al (1987). The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor.Nature325733–736. 10.1038/325733a0
75
KannanN.NeuwaldA. F. (2004). Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha.Protein Sci.132059–2077. 10.1110/ps.04637904
76
KempermannG.KuhnH. G.GageF. H. (1998). Experience-induced neurogenesis in the senescent dentate gyrus.J. Neurosci.183206–3212.
77
KessingL. V.FormanJ. L.AndersenP. K. (2010). Does lithium protect against dementia?Bipolar Disord.1287–94. 10.1111/j.1399-5618.2009.00788.x
78
KimuraT.YamashitaS.NakaoS.ParkJ. M.MurayamaM.MizorokiT.et al (2008). GSK-3beta is required for memory reconsolidation in adult brain.PLoS ONE3:e3540. 10.1371/journal.pone.0003540
79
KingM. K.PardoM.ChengY.DowneyK.JopeR. S.BeurelE. (2014). Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments.Pharmacol. Ther.1411–12. 10.1016/j.pharmthera.2013.07.010
80
KleinP. S.MeltonD. A. (1996). A molecular mechanism for the effect of lithium on development.Proc. Natl. Acad. Sci. U.S.A.938455–8459. 10.1073/pnas.93.16.8455
81
KnothR.SingecI.DitterM.PantazisG.CapetianP.MeyerR. P.et al (2010). Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years.PLoS ONE5:e8809. 10.1371/journal.pone.0008809
82
KohS. H.NohM. Y.KimS. H. (2008). Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.Brain Res.1188254–262. 10.1016/j.brainres.2007.10.064
83
KoikeH.TomiokaS.SorimachiH.SaidoT. C.MaruyamaK.OkuyamaA.et al (1999). Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein.Biochem. J.343(Pt 2)371–375. 10.1042/0264-6021:3430371
84
KokuboH.KayedR.GlabeC. G.YamaguchiH. (2005). Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer’s disease brain.Brain Res.1031222–228. 10.1016/j.brainres.2004.10.041
85
LeclercS.GarnierM.HoesselR.MarkoD.BibbJ. A.SnyderG. L.et al (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors?J. Biol. Chem.276251–260. 10.1074/jbc.M002466200
86
LeostM.SchultzC.LinkA.WuY. Z.BiernatJ.MandelkowE. M.et al (2000). Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.Eur. J. Biochem.2675983–5994. 10.1046/j.1432-1327.2000.01673.x
87
LeroyK.YilmazZ.BrionJ. P. (2007). Increased level of active GSK-3beta in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.Neuropathol. Appl. Neurobiol.3343–55. 10.1111/j.1365-2990.2006.00795.x
88
LeyheT.EschweilerG. W.StranskyE.GasserT.AnnasP.BasunH.et al (2009). Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease.J. Alzheimers Dis.16649–656. 10.3233/JAD-2009-1004
89
LiT.HawkesC.QureshiH. Y.KarS.PaudelH. K. (2006). Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta.Biochemistry453134–3145. 10.1021/bi051635j
90
LiT.PaudelH. K. (2006). Glycogen synthase kinase 3beta phosphorylates Alzheimer’s disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.Biochemistry453125–3133. 10.1021/bi051634r
91
LiaoD.HesslerN. A.MalinowR. (1995). Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice.Nature375400–404. 10.1038/375400a0
92
LiuX. S.XueQ. S.ZengQ. W.LiQ.LiuJ.FengX. M.et al (2010). Sevoflurane impairs memory consolidation in rats, possibly through inhibiting phosphorylation of glycogen synthase kinase-3beta in the hippocampus.Neurobiol. Learn. Mem.94461–467. 10.1016/j.nlm.2010.08.011
93
Llorens-MartinM.Fuster-MatanzoA.TeixeiraC. M.Jurado-ArjonaJ.UlloaF.et al (2013). GSK-3beta overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo.Mol. Psychiatry18451–460. 10.1038/mp.2013.4
94
Llorens-MartinM.Lopez-DomenechG.SorianoE.AvilaJ. (2011). GSK3beta is involved in the relief of mitochondria pausing in a tau-dependent manner.PLoS ONE6:e27686. 10.1371/journal.pone.0027686
95
LobergR. D.VeselyEBrosiusF. C.III. (2002). Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism.J. Biol. Chem.27741667–41673. 10.1074/jbc.M206405200
96
LovestoneS.HartleyC. L.PearceJ.AndertonB. H. (1996). Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules.Neuroscience731145–1157. 10.1016/0306-4522(96)00126-1
97
LucasJ. J.HernandezF.Gomez-RamosP.MoranM. A.HenR.AvilaJ. (2001). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.EMBO J.2027–39. 10.1093/emboj/20.1.27
98
Luna-MunozJ.Chavez-MaciasL.Garcia-SierraF.MenaR. (2007). Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease.J. Alzheimers Dis.12365–375.
99
LuoY.BolonB.KahnS.BennettB. D.Babu-KhanS.DenisP.et al (2001). Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation.Nat. Neurosci.4231–232. 10.1038/85059
100
LuthiA.ChittajalluR.DupratF.PalmerM. J.BenkeT. A.KiddF. L.et al (1999). Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF–GluR2 interaction.Neuron24389–399. 10.1016/S0896-6273(00)80852-1
101
LyP. T.WuY.ZouH.WangR.ZhouW.KinoshitaA.et al (2013). Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes.J. Clin. Invest.123224–235. 10.1172/JCI64516
102
MacdonaldA.BriggsK.PoppeM.HigginsA.VelayudhanL.LovestoneS. (2008). A feasibility and tolerability study of lithium in Alzheimer’s disease.Int. J. Geriatr. Psychiatry23704–711. 10.1002/gps.1964
103
MagdesianM. H.CarvalhoM. M.MendesF. A.SaraivaL. M.JulianoM. A.JulianoL. J.et al (2008). Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling.J. Biol. Chem.2839359–9368. 10.1074/jbc.M707108200
104
Manahan-VaughanD. (2010). MicroRNAs contribute to LTP in the hippocampus in vivo (Commentary on Wibrand et al.). Eur. J. Neurosci.31634–635. 10.1111/j.1460-9568.2010.07140.x
105
MartinM.RehaniK.JopeR. S.MichalekS. M. (2005). Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3.Nat. Immunol.6777–784. 10.1038/ni1221
106
MartinezA.AlonsoM.CastroA.PerezC.MorenoF. J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease.J. Med. Chem.451292–1299. 10.1021/jm011020u
107
MartinezA.GilC.PerezD. I. (2011). Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment.Int. J. Alzheimers Dis.201128050210.4061/2011/280502
108
Montenegro-VenegasC.TortosaE.RossoS.PerettiD.BollatiF.BisbalM.et al (2010). MAP1B regulates axonal development by modulating Rho-GTPase Rac1 activity.Mol. Biol. Cell213518–3528. 10.1091/mbc.E09-08-0709
109
NagyZ.EsiriM. M.CatoA. M.SmithA. D. (1997a). Cell cycle markers in the hippocampus in Alzheimer’s disease.Acta Neuropathol.946–15. 10.1007/s004010050665
110
NagyZ.EsiriM. M.SmithA. D. (1997b). Expression of cell division markers in the hippocampus in Alzheimer’s disease and other neurodegenerative conditions.Acta Neuropathol.93294–300. 10.1007/s004010050617
111
NunesP. V.ForlenzaO. V.GattazW. F. (2007). Lithium and risk for Alzheimer’s disease in elderly patients with bipolar disorder.Br. J. Psychiatry190359–360. 10.1192/bjp.bp.106.029868
112
PalomoV.SoterasI.PerezD. I.PerezC.GilC.CampilloN. E.et al (2011). Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.J. Med. Chem.548461–8470. 10.1021/jm200996g
113
PapM.CooperG. M. (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akti cell survival pathway.J. Biol. Chem.27319929–19932. 10.1074/jbc.273.32.19929
114
PapM.CooperG. M. (2002). Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway.Mol. Cell. Biol.22578–586. 10.1128/MCB.22.2.578-586.2002
115
PeineauS.TaghibiglouC.BradleyC.WongT. P.LiuL.LuJ.et al (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3beta.Neuron53703–717. 10.1016/j.neuron.2007.01.029
116
PhielC. J.WilsonC. A.LeeV. M.KleinP. S. (2003). GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides.Nature423435–439. 10.1038/nature01640
117
PiginoG. G.MorfiniPelsmanA.MattsonM. P.BradyS. T.BusciglioJ. (2003). Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport.J. Neurosci.234499–4508.
118
PlattnerF.AngeloM.GieseK. P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation.J. Biol. Chem.28125457–25465. 10.1074/jbc.M603469200
119
PlotkinB.KaidanovichO.TaliorI.Eldar-FinkelmanH. (2003). Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3.J. Pharmacol. Exp. Ther.305974–980. 10.1124/jpet.102.047381
120
PlotkinD. A.JarvikL. F. (1986). Cholinergic dysfunction in Alzheimer disease: cause or effect?Prog. Brain Res.6591–103. 10.1016/S0079-6123(08)60644-5
121
PomaraN. (2009). Lithium treatment in Alzheimer’s disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects.Psychopharmacology (Berl.)205169–170. 10.1007/s00213-009-1510-y
122
PopeW.EnamS. A.BawaN.MillerB. E.GhanbariH. A.KleinW. L. (1993). Phosphorylated tau epitope of Alzheimer’s disease is coupled to axon development in the avian central nervous system.Exp. Neurol.120106–113. 10.1006/exnr.1993.1044
123
RabacchiS. A.BaillyY.Delhaye-BouchaudN.HerrupK.MarianiJ. (1992). Role of the target in synapse elimination: studies in cerebellum of developing lurcher mutants and adult chimeric mice.J. Neurosci.124712–4720.
124
RapoportM.DawsonH. N.BinderL. I.VitekM. P.FerreiraA. (2002). Tau is essential to beta -amyloid-induced neurotoxicity.Proc. Natl. Acad. Sci. U.S.A.996364–6369. 10.1073/pnas.092136199
125
RaukA. (2008). Why is the amyloid beta peptide of Alzheimer’s disease neurotoxic?Dalton Trans.1273–1282. 10.1039/b718601k
126
RobersonE. D.Scearce-LevieK.PalopJ. J.YanF.ChengI. H.WuT.et al (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model.Science316750–754. 10.1126/science.1141736
127
RobertM.MathuranathP. S. (2007). Tau and tauopathies.Neurol. India5511–16. 10.4103/0028-3886.30420
128
RockensteinE.CrewsL.MasliahE. (2007a). Transgenic animal models of neurodegenerative diseases and their application to treatment development.Adv. Drug Deliv. Rev.591093–1102. 10.1016/j.addr.2007.08.013
129
RockensteinE.TorranceM.AdameA.ManteM.Bar-OnP.RoseJ. B.et al (2007b). Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation.J. Neurosci.271981–1991. 10.1523/JNEUROSCI.4321-06.2007
130
RyanK. A.PimplikarS. W. (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain.J. Cell Biol.171327–335. 10.1083/jcb.200505078
131
SaekiK.MachidaM.KinoshitaY.TakasawaR.TanumaS. (2011). Glycogen synthase kinase-3beta2 has lower phosphorylation activity to tau than glycogen synthase kinase-3beta1.Biol. Pharm. Bull.34146–149. 10.1248/bpb.34.146
132
SaitoY.VandenheedeJ. R.CohenP. (1994). The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells.Biochem. J.303(Pt 1)27–31.
133
SamadiA.ValderasC.de los RiosC.BastidaA.ChiouaM.Gonzalez-LafuenteL.et al (2011). Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles.Bioorg. Med. Chem.19122–133. 10.1016/j.bmc.2010.11.040
134
SanchezC.PerezM.AvilaJ. (2000). GSK3beta-mediated phosphorylation of the microtubule-associated protein 2C (MAP2C) prevents microtubule bundling.Eur. J. Cell Biol.79252–260. 10.1078/S0171-9335(04)70028-X
135
SantacruzK.LewisJ.SpiresT.PaulsonJ.KotilinekL.IngelssonM.et al (2005). Tau suppression in a neurodegenerative mouse model improves memory function.Science309476–481. 10.1126/science.1113694
136
SenguptaA.KabatJ.NovakM.WuQ.Grundke-IqbalI.IqbalK. (1998). Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules.Arch. Biochem. Biophys.357299–309. 10.1006/abbi.1998.0813
137
SenguptaA.NovakM.Grundke-IqbalI.IqbalK. (2006). Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level.FEBS Lett.5805925–5933. 10.1016/j.febslet.2006.09.060
138
SerenoL.ComaM.RodriguezM.Sanchez-FerrerP.SanchezM. B.GichI.et al (2009). A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo.Neurobiol. Dis.35359–367. 10.1016/j.nbd.2009.05.025
139
SergeantN.BrettevilleA.HamdaneM.Caillet-BoudinM. L.GrognetP.BomboisS.et al (2008). Biochemistry of tau in Alzheimer’s disease and related neurological disorders.Expert Rev. Proteomics5207–224. 10.1586/14789450.5.2.207
140
ShiptonO. A.LeitzJ. R.DworzakJ.ActonC. E.TunbridgeE. M.DenkF.et al (2011). Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation.J. Neurosci.311688–1692. 10.1523/JNEUROSCI.2610-10.2011
141
Sirerol-PiquerM.Gomez-RamosP.HernandezF.PerezM.MoranM. A.Fuster-MatanzoA.et al (2011). GSK3beta overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus.Hippocampus21910–922.
142
SoutarM. P.KimW. Y.WilliamsonR.PeggieM.HastieC. J.McLauchlanH.et al (2010). Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain.J. Neurochem.115974–983. 10.1111/j.1471-4159.2010.06988.x
143
SpittaelsK.Van den HauteC.Van DorpeJ.TerwelD.VandezandeK.LasradoR.et al (2002). Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice.Neuroscience113797–808. 10.1016/S0306-4522(02)00236-1
144
SudduthT. L.SchmittF. A.NelsonP. T.WilcockD. M. (2013). Neuroinflammatory phenotype in early Alzheimer’s disease.Neurobiol. Aging341051–1059. 10.1016/j.neurobiolaging.2012.09.012
145
SudduthT. L.WilsonJ. G.EverhartA.ColtonC. A.WilcockD. M. (2012). Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype.PLoS ONE7:e31993. 10.1371/journal.pone.0031993
146
SunW.QureshiH. Y.CaffertyP. W.SobueK.Agarwal-MawalA.et al (2002). Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules.J. Biol. Chem.27711933–11940. 10.1074/jbc.M107182200
147
SutherlandC.CohenP. (1994). The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro.FEBS Lett.33837–42. 10.1016/0014-5793(94)80112-6
148
SutherlandC.LeightonI. A.CohenP. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling.Biochem. J.296(Pt 1)15–19.
149
TakashimaA.NoguchiK.MichelG.MerckenM.HoshiM.IshiguroK.et al (1996a). Exposure of rat hippocampal neurons to amyloid beta peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta.Neurosci. Lett.20333–36. 10.1016/0304-3940(95)12257-5
150
TakashimaA.SatoM.MerckenM.TanakaS.KondoS.HondaT.et al (1996b). Localization of Alzheimer-associated presenilin 1 in transfected COS-7 cells.Biochem. Biophys. Res. Commun.227423–426. 10.1006/bbrc.1996.1523
151
TerwelD.MuyllaertD.DewachterI.BorghgraefP.CroesS.DevijverH.et al (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.Am. J. Pathol.172786–798. 10.2353/ajpath.2008.070904
152
ThotalaD. K.HallahanD. E.YazlovitskayaE. M. (2008). Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.Cancer Res.685859–5868. 10.1158/0008-5472.CAN-07-6327
153
ToledoE. M.InestrosaN. C. (2010). Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease.Mol. Psychiatry15272–285228. 10.1038/mp.2009.72
154
TownsendM.MehtaT.SelkoeD. J. (2007). Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.J. Biol. Chem.28233305–33312. 10.1074/jbc.M610390200
155
UemuraK.KuzuyaA.ShimozonoY.AoyagiN.AndoK.ShimohamaS.et al (2007). GSK3beta activity modifies the localization and function of presenilin 1.J. Biol. Chem.28215823–15832. 10.1074/jbc.M610708200
156
Van HoesenG. W.HymanB. T.DamasioA. R. (1991). Entorhinal cortex pathology in Alzheimer’s disease.Hippocampus11–8. 10.1002/hipo.450010102
157
WangH.WangR.ZhaoZ.JiZ.XuS.HolscherC.et al (2009). Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons.Brain Res.1249237–243. 10.1016/j.brainres.2008.10.046
158
WangY.JuW.LiuL.FamS.D’SouzaS.TaghibiglouC.et al (2004). alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis.J. Biol. Chem.27941267–41270. 10.1074/jbc.C400199200
159
WatcharasitP.BijurG. N.SongL.ZhuJ.ChenX.JopeR. S. (2003). Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53.J. Biol. Chem.27848872–48879. 10.1074/jbc.M305870200
160
WeiJ.LiuW.YanZ. (2010). Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3.J. Biol. Chem.28526369–26376. 10.1074/jbc.M110.121376
161
WelshG. I.ProudC. G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.Biochem. J.294(Pt 3)625–629.
162
WhitehouseP. J.PriceD. L.ClarkA. W.CoyleJ. T.DeLongM. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.Ann. Neurol.10122–126. 10.1002/ana.410100203
163
WittonJ.BrownJ. T.JonesM. W.RandallA. D. (2010). Altered synaptic plasticity in the mossy fibre pathway of transgenic mice expressing mutant amyloid precursor protein.Mol. Brain33210.1186/1756-6606-3-32
164
WuG.HeX. (2006). Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation.Biochemistry455319–5323. 10.1021/bi0601149
165
YatesC. M.SimpsonJ.GordonA.MaloneyA. F.AllisonY.RitchieI. M.et al (1983). Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down’s syndrome.Brain Res.280119–126. 10.1016/0006-8993(83)91179-4
166
ZhangH.MaQ.ZhangY. W.XuH. (2012). Proteolytic processing of Alzheimer’s beta-amyloid precursor protein.J. Neurochem.120(Suppl.1)9–21. 10.1111/j.1471-4159.2011.07519.x
167
ZhangW.ZhaoY.TongC.WangG.WangB.JiaJ.et al (2005). Hedgehog-regulated Costal2-kinase complexes control phosphorylation and proteolytic processing of Cubitus interruptus.Dev. Cell8267–278. 10.1016/j.devcel.2005.01.001
168
ZhaoC.TengE. M.SummersR. G.MingG. L.Jr.GageF. H. (2006). Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus.J. Neurosci.263–11. 10.1523/JNEUROSCI.3648-05.2006
169
ZumbrunnJ.KinoshitaK.HymanA. A.NathkeI. S. (2001). Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation.Curr. Biol.1144–49. 10.1016/S0960-9822(01)00002-1
Summary
Keywords
GSK-3β, Alzheimer disease, kinase, neurodegeneration, tau proteins
Citation
Llorens-Marítin M, Jurado J, Hernández F and Ávila J (2014) GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7:46. doi: 10.3389/fnmol.2014.00046
Received
10 February 2014
Accepted
02 May 2014
Published
21 May 2014
Volume
7 - 2014
Edited by
Akihiko Takashima, RIKEN Brain Science Institute, Japan
Reviewed by
Luc Buee, Institut National de la Santé et de la Recherche Médicale, France; Hansen Wang, University of Toronto, Canada
Copyright
© 2014 Llorens-Martín, Jurado, Hernández and Ávila.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jesús ávila and María Llorens-Martín, Centro de Biología Molecular “Severo Ochoa”, Consejo Superior de Investigaciones Cientificas, Universidad Autónoma de Madrid, C/Nicolás Cabrera 1, 28049 Madrid, Spain e-mail: javila@cbm.uam.es; mllorens@cbm.uam.es
This article was submitted to the journal Frontiers in Molecular Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.